...
ADMAMID

ADMA Biologics, Inc.

HealthcareBiotechnology
$15.57
$0.00(+2.57%)
52W$13.50
$25.67
FinancialsValuationvs UTHR
Updated Mar 1, 12:00 AM
RSI36
RS Rating31/99
Beta1.10
Volatility51%
F-Score7/9
Mkt Cap$3.7B
CONSOLIDATING

Price Action

5Y Daily
50 DMA150 DMA200 DMA

Technical Summary

CONSOLIDATING

ADMA Biologics, Inc. is in a consolidation phase, trading with mixed signals as moving averages converge. Relative strength is weak (RS Rating: 31), showing significant lag compared to the market leaders. Investors should exercise caution due to high volatility (51% annualized), which requires wider risk management.

Relative Strength
31
out of 99
Lagging
Trend Score
2/4
Minervini Criteria
CONSOLIDATING
Risk (Beta)
1.10
vs S&P 500
ABOVE MKT
52W Position
17%
from 52W low
Near Low
Trend & Momentum Analysis

Trend Template (Minervini)

CONSOLIDATING2/4 Criteria Met
CriterionValueStatus
Price > 50 SMA$17.33
50 SMA > 100 SMA$16.96
100 SMA > 150 SMA$16.87
150 SMA > 200 SMA$17.41

Price vs Moving Averages

PeriodValueSpreadSignal
20 SMA$16.23-4.09%BELOW
50 SMA$17.33-10.13%BELOW
100 SMA$16.96-8.21%BELOW
150 SMA$16.87-7.72%BELOW
200 SMA$17.41-10.55%BELOW

Price Performance

1D+2.6%
1W-4.4%
1M-4.7%
3M-18.8%
6M-10.4%
YTD-12.9%
1Y-5.0%
3Y+63.7%
52-Week Trading Range17% from low
$15.57
52W Low$13.50
52W High$25.67

Technical Indicators

RSI (14)BEARISH
35.7
305070
VCP ScoreCOOL
3/10
Base depth: 37.9%

Risk Profile

Beta
1.10
52W Vol
51%
ATR
$0.76
Max DD (1Y)
-43%

Volume Analysis

Today
15
50D Avg
1.80M
Vol Ratio
0.00x
Liquidity
MODERATE

Earnings Momentum

Q4'24+689%
$0.46
Q1'25+46%
$0.11
Q2'25+8%
$0.14
Q3'25—
$0.15
Fundamentals & Growth

Growth Trends

Compounded Sales Growth

10 Years:+53.39%
5 Years:+70.79%
3 Years:+74.01%
TTM:+27.62%

Compounded Profit Growth

10 Years:—
5 Years:—
3 Years:—
TTM:+210.25%

Stock Price CAGR

10 Years:+12.61%
5 Years:+45.11%
3 Years:+63.69%
1 Year:-5.00%

Return on Equity

10Y Avg:-153.0%
5Y Avg:-35.6%
3Y Avg:5.7%
Last Year:48.6%

Key Metrics

Market Cap$3.7B
Gross Margin51.5%
Net Margin46.4%
Piotroski F-Score7/9

More ADMA Analysis

Full Financial AnalysisDCF & Intrinsic ValueTotal Return Calculator

Compare With

ADMA vs UTHRUTHRZLABAMRNALKS

Data Dictionary

RS Rating (Relative Strength)

Measures 12-month price performance vs all stocks. Rating of 31 meansADMA outperformed 31% of all stocks. Scores >80 indicate market leaders.

Beta

Measures volatility vs S&P 500. Beta of 1.10 means 10% more volatile than market.

Piotroski F-Score

9-point financial strength score based on profitability, leverage, and efficiency. Score of 7/9. Scores 7-9 = strong, 4-6 average, 0-3 = weak.

VCP (Volatility Contraction Pattern)

Measures base formation quality. Higher scores indicate tighter consolidation near pivot points. Score of 3/10 with COOL status.

Frequently Asked Questions

Is ADMA in an uptrend right now?

ADMA has a trend score of 2/4 based on Minervini's Stage Analysis. Currently showing partial alignment - 2 of 4 trend criteria are met.

Is ADMA overbought or oversold?

ADMA's RSI (14) is 36. The stock is in neutral territory, neither overbought nor oversold.

Is ADMA outperforming the market?

ADMA has a Relative Strength (RS) Rating of 31 out of 99. ADMA is currently lagging the broader market.

Where is ADMA in its 52-week range?

ADMA is trading at $15.57, which is 61% of its 52-week high ($25.67) and 17% above its 52-week low ($13.50).

How volatile is ADMA?

ADMA has a Beta of 1.10 and 52-week volatility of 51%. It's more volatile than the S&P 500 - expect bigger swings.